相似文献
1
Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.
Clin Infect Dis. 2022 Apr 9;74(7):1271-1274. doi: 10.1093/cid/ciab647.
2
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
3
Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.
Transfus Clin Biol. 2022 May;29(2):186-187. doi: 10.1016/j.tracli.2021.10.002. Epub 2021 Oct 12.
4
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Eur J Immunol. 2021 Oct;51(10):2478-2484. doi: 10.1002/eji.202149277. Epub 2021 Sep 3.
5
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
6
Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
J Infect Dis. 2022 Mar 15;225(6):971-976. doi: 10.1093/infdis/jiab563.
7
Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.
Br J Haematol. 2023 Jan;200(2):e25-e27. doi: 10.1111/bjh.18540. Epub 2022 Nov 10.
8
High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
Emerg Infect Dis. 2022 May;28(5):1083-1084. doi: 10.3201/eid2805.220363.
9
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Transfus Clin Biol. 2021 Aug;28(3):264-270. doi: 10.1016/j.tracli.2021.04.004. Epub 2021 Apr 24.
10
Thinking more about therapy with convalescent plasma for COVID-19 patients.
Hum Vaccin Immunother. 2020 Nov 1;16(11):2601-2603. doi: 10.1080/21645515.2020.1787073. Epub 2020 Jul 9.
引用本文的文献
1
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.
Exp Hematol Oncol. 2023 Jul 27;12(1):66. doi: 10.1186/s40164-023-00426-x.
2
Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.
J Blood Med. 2023 Feb 22;14:159-187. doi: 10.2147/JBM.S397722. eCollection 2023.
3
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
4
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
mBio. 2022 Oct 26;13(5):e0175122. doi: 10.1128/mbio.01751-22. Epub 2022 Sep 22.
5
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies.
Open Forum Infect Dis. 2022 Apr 14;9(7):ofac204. doi: 10.1093/ofid/ofac204. eCollection 2022 Jul.
6
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.
Nat Commun. 2022 May 11;13(1):2583. doi: 10.1038/s41467-022-29911-3.
7
Evidence-based dosing of convalescent plasma for COVID-19 in future trials.
Clin Microbiol Infect. 2022 May;28(5):667-671. doi: 10.1016/j.cmi.2022.01.026. Epub 2022 Feb 10.
8
COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.
Mediterr J Hematol Infect Dis. 2022 Jan 1;14(1):e2022009. doi: 10.4084/MJHID.2022.009. eCollection 2022.
9
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI155114.
10
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
J Infect Dis. 2022 Mar 15;225(6):938-946. doi: 10.1093/infdis/jiab540.
本文引用的文献
1
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.
JAMA Oncol. 2021 Jun 17;7(8):1167-75. doi: 10.1001/jamaoncol.2021.1799.
2
Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors.
Clin Transl Immunology. 2021 May 16;10(5):e1285. doi: 10.1002/cti2.1285. eCollection 2021.
3
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14.
4
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb 11;40(9):507-16. doi: 10.1016/j.eimc.2021.01.013.
5
SARS-CoV-2 evolution during treatment of chronic infection.
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.
6
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
7
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4.
8
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.
Science. 2021 Feb 26;371(6532). doi: 10.1126/science.abc8378. Epub 2020 Dec 23.
9
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Blood. 2020 Nov 12;136(20):2290-2295. doi: 10.1182/blood.2020008423.
10
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment.
Nat Commun. 2020 Jul 6;11(1):3436. doi: 10.1038/s41467-020-17317-y.
Zotero 插件